Search

Your search keyword '"CANNON, CHRISTOPHER P."' showing total 6,118 results
Start Over Author "CANNON, CHRISTOPHER P."
6,118 results on '"CANNON, CHRISTOPHER P."'

51. Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the RE-DUAL PCI Trial)

Author

ten Berg, Jurrien M., Steg, Philippe Gabriel, Bhatt, Deepak L., Hohnloser, Stefan H., de Veer, Anne, Nordaby, Matias, Miede, Corinna, Kimura, Takeshi, Lip, Gregory Y.H., Oldgren, Jonas, and Cannon, Christopher P.

Published
2020
Full Text
View/download PDF

54. Author Correction: HIV-1 diversity considerations in the application of the Intact Proviral DNA Assay (IPDA)

Author

Kinloch, Natalie N., Ren, Yanqin, Alberto, Winiffer D. Conce, Dong, Winnie, Khadka, Pragya, Huang, Szu Han, Mota, Talia M., Wilson, Andrew, Shahid, Aniqa, Kirkby, Don, Harris, Marianne, Kovacs, Colin, Benko, Erika, Ostrowski, Mario A., Del Rio Estrada, Perla M., Wimpelberg, Avery, Cannon, Christopher, Hardy, W. David, MacLaren, Lynsay, Goldstein, Harris, Brumme, Chanson J., Lee, Guinevere Q., Lynch, Rebecca M., Brumme, Zabrina L., and Jones, R. Brad

Published
2021
Full Text
View/download PDF

55. HIV-1 diversity considerations in the application of the Intact Proviral DNA Assay (IPDA)

Author

Kinloch, Natalie N., Ren, Yanqin, Conce Alberto, Winiffer D., Dong, Winnie, Khadka, Pragya, Huang, Szu Han, Mota, Talia M., Wilson, Andrew, Shahid, Aniqa, Kirkby, Don, Harris, Marianne, Kovacs, Colin, Benko, Erika, Ostrowski, Mario A., Del Rio Estrada, Perla M., Wimpelberg, Avery, Cannon, Christopher, Hardy, W. David, MacLaren, Lynsay, Goldstein, Harris, Brumme, Chanson J., Lee, Guinevere Q., Lynch, Rebecca M., Brumme, Zabrina L., and Jones, R. Brad

Published
2021
Full Text
View/download PDF

70. An Update on Aspirin for Cardioprevention: Implications for Patient Care

Author

Cannon, Christopher P.

Subjects
Aspirin -- Patient outcomes, Cardiovascular diseases -- Prevention, Dose-response relationship (Biochemistry), Health
Abstract

INTRODUCTION Daily low-dose aspirin therapy has established benefit for secondary prevention in patients who have confirmed atherosclerotic cardiovascular disease (ASCVD). (1) However, published guidelines based on available primary prevention trial [...]

Published
2021
Full Text
View/download PDF

73. Quality of Care for Patients With Acute Coronary Syndromes as a Function of Hospital Revascularization Capability: Insights From Get With The Guidelines‐CAD

Author

Thukkani, Arun K, Fonarow, Gregg C, Cannon, Christopher P, Cox, Margueritte, Hernandez, Adrian F, Peterson, Eric D, Peacock, W Frank, Laskey, Warren K, Schwamm, Lee H, Bhatt, Deepak L, and Committee and Investigators, for the Get With the Guidelines Steering

Subjects
Atherosclerosis, Heart Disease - Coronary Heart Disease, Clinical Research, Cardiovascular, Heart Disease, Acute Coronary Syndrome, Aged, Aged, 80 and over, Female, Guideline Adherence, Hospitals, Humans, Male, Middle Aged, Myocardial Revascularization, Practice Guidelines as Topic, Prospective Studies, Quality of Health Care, United States, Get With the Guidelines Steering Committee and Investigators, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology
Abstract

BackgroundRevascularization availability at US hospitals varies and may impact care quality for acute coronary syndrome patients.HypothesisThe hypothesis of this study was that there would be differences in care quality at Get With The Guidelines-Coronary Artery Disease (GWTG-CAD) hospitals based on revascularization capability.MethodsFor acute coronary syndrome patients admitted to GWTG-CAD hospitals between 2000 and 2010, care quality at hospitals with or without revascularization capability was examined by assessing conformity with performance and quality measures.ResultsThis study included 95 999 acute coronary syndrome patients admitted to 310 GWTG-CAD hospitals. There were 89 000 patients admitted to 226 revascularization-capable hospitals and 6999 patients admitted to 84 hospitals without revascularization capability included. Adjusted multivariate analysis demonstrated that 8 of the 19 measures were more frequently performed in the revascularization cohort: aspirin (odds ratio [OR]: 1.41, 95% confidence interval [CI]: 1.04-1.92), clopidogrel (OR: 2.31, 95% CI: 1.78-3.00), lipid-lowering therapies at discharge (OR: 1.39, 95% CI: 1.04-1.87), lipid-lowering therapies for low-density lipoprotein >100 mg/dL (OR: 1.85, 95% CI: 1.23-2.77), achievement of blood pressure

Published
2014

75. Abstract P334: Comparing A Cuffless Device With Traditional Home Blood Pressure Monitoring In A Remote Hypertension Management Program: Primary Results Of The COOL-BP Study

Author

Fisher, Naomi D, primary, Lee, Simin, additional, Unlu, Ozan, additional, Perruchoud, David, additional, Sola, Josep, additional, Shah, Jay, additional, Chin, Nicholas, additional, Figueroa, Christian, additional, Collins, Emma, additional, Ruggierorru, Ryan, additional, Gabovitch, Dan, additional, Zelle, David, additional, Cannon, Christopher P, additional, and Scirica, Benjamin, additional

Published
2023
Full Text
View/download PDF

76. Abstract P114: Patient Preferences And Experiences With Cuffless Wrist Versus Upper Arm Cuff Blood Pressure Measurements In The CO ntinual Vs. O ccasiona L B lood P ressure Monitoring (COOL-BP) Study

Author

Unlu, Ozan, primary, Lee, Simin, additional, Gabovitch, Daniel, additional, Perruchoud, David, additional, Almeida, Tiago, additional, Collins, Emma, additional, Figueroa, Christian, additional, Ruggiero, Ryan, additional, Chin, Nicholas, additional, Cannon, Christopher P, additional, Scirica, Benjamin, additional, and Fisher, Naomi D, additional

Published
2023
Full Text
View/download PDF

77. Relationship of Race/Ethnicity With Door‐to‐Balloon Time and Mortality in Patients Undergoing Primary Percutaneous Coronary Intervention for ST‐Elevation Myocardial Infarction: Findings From Get With the Guidelines–Coronary Artery Disease

Author

Cavender, Matthew A, Rassi, Andrew N, Fonarow, Gregg C, Cannon, Christopher P, Peacock, W Frank, Laskey, Warren K, Hernandez, Adrian F, Peterson, Eric D, Cox, Margueritte, Grau‐Sepulveda, Marie, Schwamm, Lee H, and Bhatt, Deepak L

Subjects
Clinical Research, Heart Disease, Heart Disease - Coronary Heart Disease, Cardiovascular, Black or African American, Aged, Chi-Square Distribution, Female, Guideline Adherence, Health Services Accessibility, Healthcare Disparities, Hispanic or Latino, Hospital Mortality, Humans, Linear Models, Logistic Models, Male, Middle Aged, Multivariate Analysis, Myocardial Infarction, Odds Ratio, Percutaneous Coronary Intervention, Practice Guidelines as Topic, Prospective Studies, Registries, Risk Factors, Time Factors, Time-to-Treatment, Treatment Outcome, United States, White People, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology
Abstract

BackgroundPrior studies have described racial/ethnic disparities in door-to-balloon (DTB) time for patients undergoing primary percutaneous coronary intervention (PCI). We sought to compare DTB time between different racial/ethnic groups undergoing primary PCI for ST-elevation myocardial infarction in Get With the Guidelines (GWTG).HypothesisThere may be differences in D2B time associated with race/ethnicity.MethodsWe identified 7445 white (n = 6365), African American (n = 568), and Hispanic (n = 512) patients undergoing primary PCI.ResultsThere were no differences in the median DTB time between white (74 minutes; intraquartile range [IQR], 54-99), African American (77 minutes; IQR, 57-100), and Hispanic (75 minutes; IQR, 56-100) (P = 0.13) patients. There were no crude differences in DTB time ≤90 minutes; however, after adjusting for confounders, African American race was associated with lower odds of DTB time ≤90 minutes (odds ratio [OR]: 0.84; 95% confidence interval [CI]: 0.70-0.99; P = 0.04). This association was seen in African American males (OR: 0.66; 95% CI: 0.55-0.80) but not African American females (OR: 1.27; 95% CI: 0.96-1.68). Overall, Hispanic ethnicity was not associated with a difference in DTB time ≤90 minutes (OR: 0.98; 95% CI: 0.77-1.25; P = 0.88); although Hispanic males did have a slightly longer median DTB time compared with whites. During the study, the proportion of patients with DTB times ≤90 minutes increased for all groups, and mortality was similar between groups (white 3.8%, African American 3.0%, Hispanic 4.1%, P = 0.62).ConclusionsIn GWTG-Coronary Artery Disease, small differences in DTB times persist among different races/ethnicities. However, the proportion achieving DTB times ≤90 minutes has increased substantially for all patients over time, and there was no association between race/ethnicity and in-hospital mortality.

Published
2013

79. Digital Epidemiologic Research on Multilevel Risks for HIV Acquisition and Other Health Outcomes Among Transgender Women in Eastern and Southern United States: Protocol for an Online Cohort

Author

Wirtz, Andrea L, Cooney, Erin E, Stevenson, Megan, Radix, Asa, Poteat, Tonia, Wawrzyniak, Andrew J, Cannon, Christopher M, Schneider, Jason S, Haw, J Sonya, Case, James, Althoff, Keri N, Humes, Elizabeth, Mayer, Kenneth H, Beyrer, Chris, Rodriguez, Allan E, and Reisner, Sari L

Subjects
Medicine, Computer applications to medicine. Medical informatics, R858-859.7
Abstract

BackgroundThe HIV epidemic disproportionately impacts transgender women in the United States. Cohort studies identify unique risks for affected populations, but use of facility-based methods may bias findings towards individuals living in research catchment areas, more engaged in health services, or, in the case of transgender populations, those who are open about their transgender identity. Digital clinical trials and other online research methods are increasingly common, providing opportunity to reach those not commonly engaged in research. Simultaneously, there is a need to understand potential biases associated with digital research, how these methods perform, and whether they are accepted across populations. ObjectiveThis study aims to assess the feasibility of developing and implementing an online cohort of transgender women to assess risks for HIV acquisition and other health experiences. Further, this study aims to evaluate how an online cohort compares to a site-based, technology-enhanced cohort for epidemiologic research. The overarching goal is to estimate incidence of HIV and other health outcomes among transgender women in eastern and southern United States. MethodsThis substudy is part of a larger multisite prospective cohort (LITE) conducted among transgender women, which also includes a site-based, technology-enhanced cohort in 6 eastern and southern US cities. The online cohort was launched to enroll and follow participants across 72 cities in the same region and with similar demographic characteristics as the site-based cohort. Participants are followed for 24 months. Adult transgender women are recruited via convenience sampling (eg, peer referrals, social media, and dating apps). Participants reporting negative or unknown HIV status are enrolled in a baseline study visit, complete a sociobehavioral survey, and provide oral fluid specimens to test for HIV. Participants not living with HIV (lab-confirmed) at baseline are offered enrollment into the cohort; follow-up assessments occur every 6 months. ResultsEnrollment into the online cohort launched in January 2019. Active recruitment stopped in May 2019, and enrollment officially closed in August 2020. A total of 580 participants enrolled into and are followed in the cohort. A recruitment-enrollment cascade was observed across screening, consent, and completion of study activities. Implementation experiences with HIV test kits highlight the need for heavy staff engagement to support participant engagement, visit completion, and retention, even with automated digital procedures. ConclusionsThis study is responsive to increasing research interest in digital observational and intervention research, particularly for populations who are most affected by the HIV epidemic and for those who may otherwise not participate in person. The progression across stages of the recruitment-enrollment cascade provides useful insight for implementation of cohort studies in the online environment. International Registered Report Identifier (IRRID)DERR1-10.2196/29152

Published
2021
Full Text
View/download PDF

86. Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease

Author

Marston, Nicholas A., Patel, Parth N., Kamanu, Frederick K., Nordio, Francesco, Melloni, Giorgio M., Roselli, Carolina, Gurmu, Yared, Weng, Lu-Chen, Bonaca, Marc P., Giugliano, Robert P., Scirica, Benjamin M., O’Donoghue, Michelle L., Cannon, Christopher P., Anderson, Christopher D., Bhatt, Deepak L., Gabriel Steg, Philippe, Cohen, Marc, Storey, Robert F., Sever, Peter, Keech, Anthony C., Raz, Itamar, Mosenzon, Ofri, Antman, Elliott M., Braunwald, Eugene, Ellinor, Patrick T., Lubitz, Steven A., Sabatine, Marc S., and Ruff, Christian T.

Published
2021
Full Text
View/download PDF

87. Biopsychosocial Mechanisms Linking Gender Minority Stress to HIV Comorbidities Among Black and Latina Transgender Women (LITE Plus): Protocol for a Mixed Methods Longitudinal Study

Author

Rich, Ashleigh J, Williams, Jennifer, Malik, Mannat, Wirtz, Andrea, Reisner, Sari, DuBois, L Zachary, Juster, Robert Paul, Lesko, Catherine R, Davis, Nicole, Althoff, Keri N, Cannon, Christopher, Mayer, Kenneth, Elliott, Ayana, and Poteat, Tonia

Subjects
Medicine, Computer applications to medicine. Medical informatics, R858-859.7
Abstract

BackgroundBlack and Latina transgender women (TW) experience a disparate burden of HIV and related comorbidities, including poor mental health and cardiovascular disease (CVD) risks. Pervasive multilevel stigma and discrimination operate as psychosocial stressors for TW living with HIV and shape health disparities for this population. Gender-affirming hormone therapy (GAHT) is commonly used by TW to facilitate alignment of the body with gender identity; in the context of stigma, GAHT may both improve mental health and increase CVD risks. ObjectiveThis study aims to quantify the longitudinal relationship between stigma and chronic stress among black and Latina TW living with HIV. Secondary objectives include identifying pathways linking chronic stress to HIV comorbidities and exploring chronic stress as a mediator in the pathway linking stigma and GAHT to CVD comorbidities. MethodsThis US-based mixed methods longitudinal study will enroll a prospective cohort of 200 black and Latina TW living with HIV, collecting quantitative survey data, qualitative interviews, and biomarkers of chronic stress. Interviewer-administered surveys will include validated psychosocial measures of self-reported stigma and discrimination, perceived stress, CVD risk factors, mental health, access to gender-affirming care, coping, and social support. Medical record abstraction will collect data on GAHT use, CD4 count, HIV viral load, antiretroviral therapy, treatment, and comorbid conditions. Clinical measures will include physiological biomarkers as well as salivary and blood-based biomarkers of chronic stress. Survey data will be collected every 6 months (baseline, and 6, 12, 18, and 24 months), and biospecimens will be collected at baseline and at 12 and 24 months. A purposive subsample (stratified by use of GAHT and presence of depressive symptoms) of 20 to 30 TW living with HIV will be invited to participate in in-depth interviews at 6 and 18 months to explore experiences of intersectional stigma, chronic stress, and the role of GAHT in their lives. ResultsThis study was funded by the National Institute on Minority Health and Health Disparities in December 2018. The study community advisory board and scientific advisors provided critical input on study design. Recruitment began in October 2019 (n=29 participants as of submission) and data collection will continue through 2022, with publication of baseline results anticipated summer 2021. ConclusionsThis study will focus on black and Latina TW living with HIV, an understudied health disparities population, advance both stigma and intersectionality research, and move chronic stress physiology research toward a more nuanced understanding of sex and gender. The comprehensive methodology will support the exploration of the role of exogenous estrogen in the pathways between stress and HIV comorbidities, elucidating the role of GAHT in the stress-health relationship. Finally, this study will provide longitudinal evidence of the impact of stigma-related chronic stress on the lives of black and Latina TW living with HIV integrating qualitative and quantitative data with psychosocial, clinical, and biological measures. International Registered Report Identifier (IRRID)DERR1-10.2196/17076

Published
2020
Full Text
View/download PDF

89. Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial

Author

Cosentino, Francesco, Cannon, Christopher P., Cherney, David Z.I., Masiukiewicz, Urszula, Pratley, Richard, Dagogo-Jack, Sam, Frederich, Robert, Charbonnel, Bernard, Mancuso, James, Shih, Weichung J., Terra, Steven G., Cater, Nilo B., Gantz, Ira, and McGuire, Darren K.

Published
2020
Full Text
View/download PDF

90. Abstract 16195: Socioeconomic Disadvantage is Associated With Higher Long-Term Cardiovascular Mortality Following Myocardial Infarction: The YOUNG-MI Registry

Author

Berman, Adam N, Biery, David W, Singh, Avinainder, Baek, Jonggyu, Wu, Wanda Y, Wadhera, Rishi K, Divakaran, Sanjay, DeFilippis, Ersilia M, Hainer, Jon, Cannon, Christopher P, Plutzky, Jorge, Polk, Donna M, Nasir, Khurram, DI CARLI, MARCELO F, Ash, Arlene, Bhatt, Deepak L, and Blankstein, Ron

Published
2020
Full Text
View/download PDF

93. Abstract 13702: A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients With Cardiometabolic Disease

Author

Patel, Parth N, Marston, Nicholas A, Kamanu, Frederick K, Weng, Lu Chen, Bonaca, Marc P, Giugliano, Robert P, Scirica, Benjamin M, OʼDonoghue, Michelle L, Cannon, Christopher P, ANDERSON, Christopher D, Bhatt, Deepak L, Steg, Philippe G, Cohen, Marc, Storey, Robert F, Sever, Peter S, Keech, Anthony C, RAZ, Itamar, Mosenzon, ofri, Braunwald, Eugene, Ellinor, Patrick T, Lubitz, Steven A, Sabatine, Marc S, and Ruff, Christian T

Published
2020
Full Text
View/download PDF

94. Abstract 13214: Underuse of Combination Pharmacotherapy for Management of Dyslipidemia versus Diabetes and Hypertension Among Patients With Atherosclerotic Cardiovascular Disease (ascvd): Insights From the Getting to an Improved Understanding of Low-density Lipoprotein-cholesterol and Dyslipidemia Management (gould) Registry

Author

Agha, Ali M, Kosiborod, Mikhail N, De Lemos, James A, Rosenson, Robert S, Gao, Qi, Mues, Katie, Alam, Shushama, Bhatt, Deepak L, Cannon, Christopher P, and Ballantyne, Christie M

Published
2020
Full Text
View/download PDF

99. Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial.

Author

Pandey, Ambarish, Kolkailah, Ahmed A, Cosentino, Francesco, Cannon, Christopher P, Frederich, Robert C, Cherney, David Z I, Dagogo-Jack, Samuel, Pratley, Richard E, Cater, Nilo B, Gantz, Ira, Mancuso, James P, and McGuire, Darren K

Subjects
VENTRICULAR ejection fraction, HEART failure, TYPE 2 diabetes, HOSPITAL care, SODIUM-glucose cotransporter 2 inhibitors
Abstract

This article discusses the results of a post-hoc analysis of the VERTIS CV trial, which examined the effects of the medication ertugliflozin on the risk of hospitalization for heart failure (HHF) in patients with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease. The study found that ertugliflozin significantly reduced the risk of first HHF in the overall cohort of participants. However, the treatment effect was more pronounced in individuals with a pre-trial ejection fraction (EF) of less than 45% and attenuated in those with an EF greater than 60%. These findings contribute to the understanding of the efficacy of SGLT2 inhibitors in reducing the risk of HHF across different EF ranges. [Extracted from the article]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results